PD14-01 CLINICAL EXPERIENCE WITH LUTETIUM 177-LABELED PSMA-I&T FOR RADIOLIGAND THERAPY IN 100 CONSECUTIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II1 Apr 2018PD14-01 CLINICAL EXPERIENCE WITH LUTETIUM 177-LABELED PSMA-I&T FOR RADIOLIGAND THERAPY IN 100 CONSECUTIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Matthias Heck, Sebastian Schwaiger, Karina Knorr, Margitta Retz, Tobias Maurer, Friederike Janssen, Calogero D`Alessandria, Hans-Jürgen Wester, Jürgen Gschwend, Markus Schwaiger, Robert Tauber, and Matthias Eiber Matthias HeckMatthias Heck More articles by this author , Sebastian SchwaigerSebastian Schwaiger More articles by this author , Karina KnorrKarina Knorr More articles by this author , Margitta RetzMargitta Retz More articles by this author , Tobias MaurerTobias Maurer More articles by this author , Friederike JanssenFriederike Janssen More articles by this author , Calogero D`AlessandriaCalogero D`Alessandria More articles by this author , Hans-Jürgen WesterHans-Jürgen Wester More articles by this author , Jürgen GschwendJürgen Gschwend More articles by this author , Markus SchwaigerMarkus Schwaiger More articles by this author , Robert TauberRobert Tauber More articles by this author , and Matthias EiberMatthias Eiber More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.787AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To report our clinical experience with 177Lutetium-labeled prostate-specific membrane antigen-ligand (177Lu-PSMA-I&T) for systemic radioligand therapy in 100 consecutive patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS All patients were treated under a review board-approved compassionate use protocol. Eligibility criteria for 177Lu-PSMA-I&T therapy included previous treatment with abiraterone or enzalutamide, previous taxane-based chemotherapy or ineligibility to taxanes as well as positive 68Ga-PSMA tracer uptake of metastases in a prior PET-scan. Intravenous treatment with 177Lu-PSMA-I&T was given 6- to 8-weekly with an activity of 7.4GBq up to 6 cycles in patients without clinical or radiographic progression. We report prostate-specific antigen (PSA) decline, PSA progression-free survival (PSA-PFS), clinical progression-free survival (cPFS) and overall survival (OS) as well as toxicity. RESULTS Median age was 72 years (range 46-85) and median PSA level was 164 ng/ml (range 0-6178). Bone, lymph node and visceral metastases were present in 94%, 85% and 33% of patients, respectively. The median number of previous treatment regimens for mCRPC was 3 (range 1-6) and 84% of patients were pretreated with chemotherapy. At the time of evaluation, 286 cycles with 177Lu-PSMA-I&T were applied (median 2 cycles per patient, range 1-6), while treatment was still ongoing in 27% of patients. Overall, 4 and 6 cycles were applied in 33 and 15 patients, respectively. PSA decline ≥30%, ≥50% and ≥90% was achieved in 40%, 32% and 9% of patients, respectively. Median PSA-PFS was 3.4 months (95%CI 2.7-4.0), median cPFS was 4.1 months (95%CI 2.5-5.7) and median OS was 12.2 months (95%CI 8.8-15.7). Treatment-emergent hematologic grade 3/4 toxicities were anemia in 7%, thrombocytopenia in 5% and neutropenia in 4% of patients. Grade 3/4-non-hematologic toxicities were not observed. The main non-hematologic grade 1/2 toxicities were dry mouth in 18%, fatigue in 16% and loss of appetite in 9% of patients. CONCLUSIONS Radioligand therapy with 177Lu-PSMA I&T appears to be safe and active in late-stage mCRPC. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e304 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Matthias Heck More articles by this author Sebastian Schwaiger More articles by this author Karina Knorr More articles by this author Margitta Retz More articles by this author Tobias Maurer More articles by this author Friederike Janssen More articles by this author Calogero D`Alessandria More articles by this author Hans-Jürgen Wester More articles by this author Jürgen Gschwend More articles by this author Markus Schwaiger More articles by this author Robert Tauber More articles by this author Matthias Eiber More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...